TRAW Stock Summary and Trading Ideas (Traws Pharma | NASDAQ:TRAW)

Traws Pharma Inc is a clinical-stage biopharmaceutical company dedicated to developing novel therapies to target critical threats to human health in respiratory viral diseases. It is advancing novel investigational antiviral agents that have potent activity against difficult-to-treat or resistant virus strains that threaten human health. Its product candidates are Tivoxavir marboxil, Ratutrelvir, and Narazaciclib.

Traws Pharma trades on the NASDAQ stock market under the symbol TRAW.

As of April 10, 2026, TRAW stock price declined to $1.48 with 33,690 million shares trading.

TRAW has a beta of -1.02, meaning it tends to be less sensitive to market movements. TRAW has a correlation of 0.02 to the broad based SPY ETF.

TRAW has a market cap of $11.83 million. This is considered a Sub-Micro Cap stock.

The top ETF exchange traded funds that TRAW belongs to (by Net Assets): VXF.

TRAW has underperformed the market in the last year with a price return of -15.4% while the SPY ETF gained +30.9%. However, in the short term, TRAW had mixed performance relative to the market. It has outperformed in the last 3 months, returning +10.4% vs -1.8% return in SPY. But in the last 2 weeks, TRAW shares have been beat by the market, returning -15.9% compared to an SPY return of +7.2%.

TRAW support price is $1.37 and resistance is $1.63 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that TRAW shares will trade within this expected range on the day.